Publikationen, an denen er mitarbeitet MARCOS FERNANDEZ FONDEVILA (13)

2024

  1. Inhibition of hepatic p63 ameliorates steatohepatitis with fibrosis in mice

    Molecular Metabolism, Vol. 85

  2. p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

    Cell Reports Medicine, Vol. 5, Núm. 2

2023

  1. Hepatic levels of S-adenosylmethionine regulate the adaptive response to fasting

    Cell Metabolism, Vol. 35, Núm. 8, pp. 1373-1389.e8

  2. Hepatic p63 regulates glucose metabolism by repressing SIRT1

    Gut, Vol. 72, Núm. 3, pp. 472-483

  3. Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

    Molecular Metabolism, Vol. 75

  4. Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

    Cell Metabolism, Vol. 35, Núm. 9, pp. 1630-1645.e5

2022

  1. Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function

    Journal of Hepatology, Vol. 76, Núm. 1, pp. 11-24

  2. Inhibition of carnitine palmitoyltransferase 1A in hepatic stellate cells protects against fibrosis

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 15-28

  3. O-GlcNAcylation: A Sweet Hub in the Regulation of Glucose Metabolism in Health and Disease

    Frontiers in Endocrinology, Vol. 13

2021

  1. O-GlcNAcylated p53 in the liver modulates hepatic glucose production

    Nature Communications, Vol. 12, Núm. 1

  2. Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points

    Journal of Hepatology

  3. The L-α-Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis

    Hepatology, Vol. 73, Núm. 2, pp. 606-624

2018

  1. Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis

    Molecular Metabolism, Vol. 8, pp. 132-143